06.10.2021 • News

Epsilyte Buys StyroChem Canada

Epsilyte Holdings, a leading North American producer of advanced materials used in construction, packaging and safety equipment, has acquired StyroChem, a Canadian expandable polystyrene (EPS) manufacturer, from PMC Capital Partners, which has owned the business since August 2019. Financial terms were not disclosed.

The acquisition, said Epsilyte, creates one of North America’s largest producers of EPS, with three production sites and more than 300 employees. StyroChem brings a production site in Montreal, Quebec, Canada.

“Our advanced materials are already key enablers of carbon neutrality due to their almost unmatched insulative properties. This acquisition further strengthens our ability to enhance our portfolio through StyroChem’s unique and efficient operational technology enabling us to better serve customers with more sustainable products and true value creation,” said Brad Crocker, Epsilyte’s president and CEO.

Epsilyte is owned by Balmoral Funds and management. The firm was created in September 2020 after Balmoral Funds bought the EPS business of Flint Hills Resources through a management buyout led by Crocker.

Author: Elaine Burridge, Freelance Journalist

Epsilyte, a leading North American producer of advanced materials used in...
Epsilyte, a leading North American producer of advanced materials used in construction, packaging and safety equipment, has acquired StyroChem, a Canadian expandable polystyrene (EPS) manufacturer, from PMC Capital Partners, which has owned the business since August 2019. (c) StyroChem

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read